Buscar

Estamos realizando la búsqueda. Por favor, espere...

Detalle_Publicacion

Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant

Abstract: Background: Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are important data to target booster vaccine programs. The primary aim of the current study was to measure humoral responses to 2 doses of COVID-19 vaccine. Secondary aims included the determination of factors predicting breakthrough infection. Methods: COVID-19 vaccination and Biomarkers in cirrhosis And post-Liver Transplantation is a prospective, multicenter, observational case-control study. Participants were recruited at 4-10 weeks following first and second vaccine doses in cirrhosis [n = 325; 94% messenger RNA (mRNA) and 6% viral vaccine], autoimmune liver disease (AILD) (n = 120; 77% mRNA and 23% viral vaccine), post-liver transplant (LT) (n = 146; 96% mRNA and 3% viral vaccine), and healthy controls (n = 51; 72% mRNA, 24% viral and 4% heterologous combination). Serological end points were measured, and data regarding breakthrough SARS-CoV-2 infection were collected. Results: After adjusting by age, sex, and time of sample collection, anti-Spike IgG levels were the lowest in post-LT patients compared to cirrhosis (p < 0.0001), AILD (p < 0.0001), and control (p = 0.002). Factors predicting reduced responses included older age, Child-Turcotte-Pugh B/C, and elevated IL-6 in cirrhosis; non-mRNA vaccine in AILD; and coronary artery disease, use of mycophenolate and dysregulated B-call activating factor, and lymphotoxin-alpha levels in LT. Incident infection occurred in 6.6%, 10.6%, 7.4%, and 15.6% of cirrhosis, AILD, post-LT, and control, respectively. The only independent factor predicting infection in cirrhosis was low albumin level. Conclusions: LT patients present the lowest response to the SARS-CoV-2 vaccine. In cirrhosis, the reduced response is associated with older age, stage of liver disease and systemic inflammation, and breakthrough infection with low albumin level

Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria

 Fuente: Hepatology Communications, 2023, 7(11), e0273

Editorial: Wiley Periodicals, Inc. on behalf of the American Association for the Study of Liver Diseases

 Año de publicación: 2023

Nº de páginas: 25

Tipo de publicación: Artículo de Revista

 DOI: 10.1097/HC9.0000000000000273

ISSN: 2471-254X

Autoría

MEHTA, GAUTAM

RIVA, ANTONIO

PILAR BALLESTER, MARIA

USON, EVA

PUJADAS, MONTSERRAT

CARVALHO-GOMES, ÂNGELA

SAHUCO, IVAN

BONO, ARIADNA

AMICO, FEDERICO D'

VIGANÒ, RAFFAELA

DIAGO, ELENA

TORMO LANSEROS, BEATRIZ

INGLESE, ELVIRA

MARTINEZ VAZQUEZ, DANI

SHARMA, RAJNI

PHOEBE TSOU, HIO LAM

HARRIS, NICOLA

BROEKHOVEN, ANNELOTTE

KOKKERT, MARJOLEIN